Clinical Trial Update: The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion [NA]

View source ↗

Summary

A completed clinical trial evaluating how acipimox influences glucagon-like peptide-1 (GLP-1) secretion in individuals with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Acipimox (Acipimox)

Snippet

Sponsor: University of Aarhus | Conditions: Diabetes Mellitus Type 2 | NA | Status: COMPLETED